Britain and America have reached a major commercial pact that will guarantee no duties on British pharmaceutical products being sold in the American market.
Key Provisions of the Accord
As part of the deal, the UK has agreed to raise spending on pharmaceuticals through the public health system. This move secures that tariffs on these vital products will remain at nothing for a period of three years.
This deal is in response to previous warnings to significantly raise duties on patented drug imports, with potential rates floated as high as one hundred percent.
"This agreement with the UK strengthens the global environment for innovative medicines and establishes much-needed fairness to American-British medicine commerce," an announcement said.
Commercial Impact
Drugs constitute one of the UK's largest goods shipped to the United States, which is clearly the largest destination for major companies like GSK and AstraZeneca.
Statistics indicate that in the one-year period to the end of last September, the UK shipped pharmaceutical products worth billions to the US. This figure accounted for a significant portion of British export trade in that span.
"This agreement safeguards jobs, increases funding and paves the way for the UK to become a worldwide center for life sciences," a government official remarked.
Key UK Commitments
The agreement includes several specific changes from the United Kingdom:
- Revised Affordability Limit: The UK will lift the affordability limit at which it considers new medicines to be too expensive by a quarter.
- Boosted Medicine Funding: There is a target to increase total health service expenditure on drugs from 0.3% of GDP to 0.6 percent over the next decade.
- Payback Limit: The amount drug companies must pay back to the NHS to control costs will be restricted at 15%. Previously, refunds topped 20%.
Recent Tensions
The deal follows a protracted row between the sector and the ministers over drug pricing and approval rates.
This friction were intensified by arguments that American consumers were paying significantly more for the same drugs than consumers in the UK and Europe.
Recently, several large manufacturing plans in the UK have been delayed or abandoned, while substantial funding commitments have been pledged toward projects in the United States.
A senior figure publicly accepted that the NHS had to invest a greater share on drugs, noting that its spending on drugs had decreased as a share of its resources over the previous ten-year period.
